Skip to main content
SpringerLink
Log in

Neocarzinostatin

The Past, Present, and Future of Anticancer Drug

  • Book
  • © 1997

Overview

Editors:
  1. Hiroshi Maeda

    1. Department of Microbiology, Kumamoto University School of Medicine, Kumamoto, 860, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Kiyoto Edo

    1. Pharmacy, Fukushima Medical College Hospital, Fukushima, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Nakao Ishida

    1. Tohoku University, Sendai, Miyagi, Japan
      Sendai Institute of Microbiology, Sendai, Miyagi, 980, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (13 chapters)

  1. Front Matter

    Pages II-XVI
    Download chapter PDF

  2. Introduction

    • Hiroshi Maeda, Kiyoto Edo, Nakao Ishida
    Pages 1-2

  3. Chemical Structure of the Apoprotein of Neocarzinostatin

    • Kenji Kuromizu, Hiroshi Maeda
    Pages 3-22

  4. Neocarzinostatin Chromophore: Structure and Mechanism of DNA Cleavage

    • Kiyoto Edo, Yoshio Koide
    Pages 23-45

  5. Synthesis and Chemistry of Nine-Membered Cyclic Enediyne Chromophores of Chromoprotein Antitumor Antibiotics

    • Masahiro Hirama
    Pages 47-82

  6. Solution Structure of Neocarzinostatin Determined by Homonuclear Two-Dimensional Nuclear Magnetic Resonance

    • Hiroyuki Takashima, Yuji Kobayashi
    Pages 83-107

  7. Three-Dimensional Structure of Neocarzinostatin

    • Kyoung-Hee Kim, Andrew D. Myers, Douglas C. Rees
    Pages 109-128

  8. The Biochemical Mechanisms Involved in the Biological Effects Induced by Neocarzinostatin (NCS) and the NCS Chromophore

    • Kenzo Ohtsuki, Yasushi Ono
    Pages 129-154

  9. Activation of Neocarzinostatin by NADPH/Cytochrome P-450 Reductase: Proposal of an Ultimate Mode of Action in Cells Involving Oxygen Free Radicals

    • Takaaki Akaike, Keizo Sato, Hiroshi Maeda
    Pages 155-166

  10. Immunomodulating Antitumor Mechanisms of SMANCS

    • Fujio Suzuki, Makiko Kobayashi
    Pages 167-186

  11. Host-Mediated Antitumor Activity Induced by Neocarzinostatin and Its Polymer-Conjugated Derivative SMANCS in Tumor-Bearing Mice

    • Etsuko Masuda, Hiroshi Maeda
    Pages 187-204

  12. Pharmacological Uniqueness and Clinical Effects of Neocarzinostatin

    • Hiroshi Maeda
    Pages 205-226

  13. Metamorphosis of Neocarzinostatin to SMANCS: Chemistry, Biology, Pharmacology, and Clinical Effect of the First Prototype Anticancer Polymer Therapeutic

    • Hiroshi Maeda, Toshimitsu Konno
    Pages 227-267

  14. Supplementary Materials: Publications on Neocarzinostatin or Related Subjects, in English, 1960–1981

    • Shigehiro Matsumoto, Hiroshi Maeda, Nakao Ishida
    Pages 269-277

  15. Back Matter

    Pages 279-287
    Download chapter PDF
Back to top

Keywords

About this book

The 20th century has witnessed the great benefits of the development of antibi­ otics, which became a reality after World War IL More than 50 years ago I witnessed the miraculous therapeutic power of penicillin, when I was a student at the Tohoku University Medical School's Department of Bacteriology in Sendai, Japan. The late Dr. Kondo was a graduate student in the department at that time and developed the first crude penicillin preparation in Japan which was applied with dramatic results in two patients. Although there was patient-family consent at that time, ethics committees, randomization. mutagenesis tests, distribution studies, purity-criteria, and phar­ macokinetics were not yet in existence. Today, regulatory procedures have com­ plicated the whole drug-approval process. For example, any new antibiotics that have been proven effective in laboratory studies against gram-negative bacteria, as might exist in deadly plague bacteria, must still undergo a long and enormously costly regulatory process before they can be introduced to benefit society, and before government insurance can be applied.

Editors and Affiliations

  • Department of Microbiology, Kumamoto University School of Medicine, Kumamoto, 860, Japan

    Hiroshi Maeda

  • Pharmacy, Fukushima Medical College Hospital, Fukushima, Japan

    Kiyoto Edo

  • Tohoku University, Sendai, Miyagi, Japan

    Nakao Ishida

  • Sendai Institute of Microbiology, Sendai, Miyagi, 980, Japan

    Nakao Ishida

Bibliographic Information

  • Book Title: Neocarzinostatin

  • Book Subtitle: The Past, Present, and Future of Anticancer Drug

  • Editors: Hiroshi Maeda, Kiyoto Edo, Nakao Ishida

  • DOI: https://doi.org/10.1007/978-4-431-66914-2

  • Publisher: Springer Tokyo

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Japan 1997

  • Softcover ISBN: 978-4-431-66916-6Published: 03 October 2013

  • eBook ISBN: 978-4-431-66914-2Published: 11 November 2013

  • Edition Number: 1

  • Number of Pages: XVI, 287

  • Number of Illustrations: 45 b/w illustrations, 13 illustrations in colour

  • Topics: Cancer Research

Publish with us

Policies and ethics

Back to top

Search

Navigation